Patents Assigned to Gilead Sciences, Inc.
  • Patent number: 12122776
    Abstract: The present disclosure relates generally to certain tetracyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
    Type: Grant
    Filed: May 12, 2023
    Date of Patent: October 22, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Lan Jiang, David W. Lin, Michael L. Mitchell, Ezra Roberts, Gregg M. Schwarzwalder
  • Patent number: 12122764
    Abstract: The present disclosure relates to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2, including cancer.
    Type: Grant
    Filed: December 20, 2022
    Date of Patent: October 22, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Zhimin Du, Musong Kim, Rhiannon Thomas-Tran, Michael T. Tudesco, Chandrasekar Venkataramani
  • Patent number: 12122765
    Abstract: The present disclosure relates to methods and intermediates useful for preparing a compound of formula I: or a co-crystal, solvate, salt or combination thereof.
    Type: Grant
    Filed: June 5, 2023
    Date of Patent: October 22, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Anna Michelle Wagner, Scott Alan Wolckenhauer
  • Patent number: 12121511
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: October 22, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
  • Patent number: 12121529
    Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Type: Grant
    Filed: November 16, 2023
    Date of Patent: October 22, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Jinfa Du, Dhanapalan Nagarathnam, Michael Joseph Sofia, Peiyuan Wang
  • Patent number: 12116380
    Abstract: Phospholipid compounds and methods of using the same, singly or in combination with additional agents, and pharmaceutical formulations of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: August 16, 2022
    Date of Patent: October 15, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Byoung-Kwon Chun, Michael O. Clarke, Deeba Ensan, Rao V. Kalla, Richard L Mackman, Jagadeesh N. Manda, Devan Naduthambi, Dustin S. Siegel
  • Patent number: 12110294
    Abstract: The present disclosure provides pyrimidine dione compounds of Formula I and pharmaceutical compositions thereof, for treating cancer, including solid tumors either-used alone or in combination with other anti-cancer agents.
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: October 8, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark J. Bartlett, Gregory F. Chin, Michael O. Clarke, Jennifer L. Cosman, Deeba Ensan, Bindu Goyal, Stephen Ho, Hon C. Hui, Richard L. Mackman, Michael R. Mish, Scott D. Schroeder, Nathan D. Shapiro, Dustin S. Siegel, Doris T. Tang, Hai Yang
  • Patent number: 12110305
    Abstract: Compounds, compositions, and method useful for treating a viral infection, such as human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, are disclosed. In particular, prodrugs of phosphonamide nucleotide analogues and methods for their preparation and use as therapeutic or prophylactic agents are disclosed.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: October 8, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Daniel H. Byun, Byoung-Kwon Chun, Michael O. Clarke, Petr Jansa, Devan Naduthambi, Neil H. Squires
  • Patent number: 12102625
    Abstract: Disclosed herein are novel solid forms of FXR agonists. The disclosure also relates to pharmaceutical compositions containing one or more of the solid forms disclosed herein, as well as methods of using the solid forms in the treatment of conditions mediated by FXR. The disclosure also relates to methods for obtaining such solid forms.
    Type: Grant
    Filed: October 31, 2022
    Date of Patent: October 1, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Derek M. Dalton, Peter C. Fung, Nolan Griggs, Jeffrey N. Hemenway, Olga V. Lapina, Matthew M. Logan, Sean T. Neville, Bryan J. Reynolds, Hui-Wen Shih, Anna M. Wagner
  • Patent number: 12102677
    Abstract: Provided are methods for identifying patient populations infected with HIV that can be targeted by antibodies that bind to HIV gp120 V3 glycan region.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: October 1, 2024
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Brian Moldt, Craig S. Pace
  • Publication number: 20240307502
    Abstract: The present disclosure relates to a method of treating non-alcoholic steatohepatitis (NASH) comprising administering to a subject with NASH a combination therapy comprising semaglutide, firsocostat, and/or cilofexor.
    Type: Application
    Filed: May 24, 2024
    Publication date: September 19, 2024
    Applicants: Gilead Sciences, Inc., Novo Nordisk A/S
    Inventors: Constantine Stephen Djedjos, Bryan John McColgan, Robert Paul Myers, Gangadharan Mani Subramanian, Lene Melchiorsen, Morten Hansen
  • Patent number: 12091404
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: September 17, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Gediminas J. Brizgys, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Michael L. Mitchell, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • Patent number: 12091426
    Abstract: The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: September 17, 2024
    Assignees: Nurix Therapeutics, Inc., Gilead Sciences, Inc.
    Inventors: John Buell, Frederick Cohen, Ryan Pemberton, Hunter P. Shunatona, Lan Wang, Mark Edward Zak
  • Patent number: 12091420
    Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
    Type: Grant
    Filed: October 3, 2023
    Date of Patent: September 17, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen E. Ammann, Xinpei Cai, Eda Y. Canales, Weng K. Chang, Gregory F. Chin, Henok H. Kinfe, Jessica L. Mckinley, Michael R. Mish, Devan Naduthambi, Jason K. Perry, Kevin X. Rodriguez, Scott D. Schroeder, Christopher J. Swank, Joshua J. Van Veldhuizen
  • Patent number: 12084467
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.
    Type: Grant
    Filed: December 2, 2022
    Date of Patent: September 10, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhimin Du, Julie Farand, Tezcan Guney, Darryl Kato, John O. Link, James B. C. Mack, Dong Min Mun, William J. Watkins, Jennifer R. Zhang
  • Patent number: 12084455
    Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
    Type: Grant
    Filed: April 7, 2021
    Date of Patent: September 10, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Elbert Chin, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, John O. Link, Nathan Shapiro, Teresa Alejandra Trejo Martin, Zheng-Yu Yang
  • Patent number: 12084510
    Abstract: Herein described are antibodies to epidermal growth factor receptor (EGER) having an EGER binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: September 10, 2024
    Assignees: Gilead Sciences, Inc., National Research Council of Canada
    Inventors: Ilia Alexandre Tikhomirov, Maria L. Jaramillo, Maureen D. O'Connor-McCourt, Traian Sulea, Renald Gilbert, Bruno Gaillet, Jason Baardsnes, Myriam Banville, Suzanne Grothe
  • Patent number: 12077537
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.
    Type: Grant
    Filed: February 15, 2023
    Date of Patent: September 3, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Chienhung Chou, Scott E. Lazerwith, John O. Link, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang
  • Patent number: 12070455
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.
    Type: Grant
    Filed: September 8, 2022
    Date of Patent: August 27, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Yasamin Moazami, Scott D. Schroeder, Daniel G. Shore
  • Patent number: 12060351
    Abstract: A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: August 13, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen Ammann, Elizabeth M. Bacon, Gediminas Brizgys, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Marilyn Ndukwe, Marina Shatskikh, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel